Whether preparing for a new specialty product launch, or working to modify or enhance an existing channel strategy or support model, pharma and biotech manufacturers regularly turn to Therigy. With Therigy, pharma manufacturers get expert support in channel strategy and service model design — specific to specialty therapies and patient populations, as well as development, implementation, and ongoing management.
Tap into the right disease state knowledge base. Therigy’s subject matter expert consultants have extensive backgrounds in consulting with manufacturers and specialty pharmacies to meet their objectives in supporting specialty disease states such as Alpha-1 Antitrypsin Disorder, Hemophilia, Hepatitis C, Hereditary Angioedema, Oncology, Neurological Disease, Rheumatoid Arthritis, Pulmonary Arterial Hypertension, and many others.
Our pharma consulting services help build effective product strategy and service models through:
Therigy meets each client’s unique project needs by drawing on the extensive experience of our subject matter expert consultants. Our collective knowledge base, combined with the practical application of best practices, and a keen understanding of past and future trends, achieves the greatest economic and clinical success for our clients.
Click the arrows below to learn more about our projects.
A pharma manufacturer contracted Therigy 20 months prior to the launch of its novel treatment for Hepatitis C Virus. Specifically. Therigy was engaged for the following support:
A well-known, existing specialty therapy in open distribution was challenged by the pending approval of an additional orphan indication. The brand was challenged by FDA comments and concerns regarding the potential for dosing errors and a request to perform additional HF studies. Therigy was engaged to support the design/ development of a limited distribution and channel support strategy for the new orphan indication.
Therigy rapidly worked with the brand and managed markets teams to:
A large pharma manufacturer engaged Therigy to better understand and develop an engagement strategy for influential customers to develop specialty pharmacy capabilities. The project outcome was the development of a process to determine whether to grant such organizations access to the manufacturer's limited distribution therapies. For the project, Therigy performed the following:
A pharmaceutical manufacturer engaged Therigy to develop a network of specialty pharmacies with the objective of delivering a branded adherence program across the participating network specialty pharmacies. Therigy’s program Included design, development, and execution of a pilot program, broad program roll-out, data aggregation and reporting. Key Therigy activities included: